盟科药业(688373.SH)与海鲸药业签订战略合作协议

Group 1 - The core agreement between Mengke Pharmaceutical and Nanjing Haijing Pharmaceutical involves strategic cooperation to enhance market access and service value, leveraging existing commercial channels for deep commercialization efforts [1][2] - The sales revenue targets for the products from 2026 to 2028 are set at 260 million, 388 million, and 600 million respectively, contingent on successful market resource integration [1] - Nanjing Haijing specializes in raw material drug development and will utilize its expertise to reduce product costs and enhance profitability for Mengke Pharmaceutical [1] Group 2 - Both companies are responding to the "Healthy China 2030" strategy by establishing a product innovation cooperation platform focused on innovative research for disease prevention and treatment [2] - The collaboration aims to explore the value of existing products and resources in therapeutic drugs and bioproducts, fostering new product and service development [2] - There will be a focus on optimizing capital structure and resource utilization in the capital markets as part of the partnership [2]